Eidos Therapeutics, a BridgeBio company
AG10
Amyloid Cardiomyopathy
Countdown
389days
Phase 2 readout · ~ Jul 31, 2027 estimated
What's at stake
Phase 2 trial results for AG10 in Amyloid Cardiomyopathy are due ~ Jul 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT03536767: Phase 2 trial, sponsor Eidos Therapeutics, a BridgeBio company, drug AG10. Primary completion date 2027-07 (estimated).”